Immunic is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases.
The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026.
